Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Thomas Decker

6PUBLICATIONS

11CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Mar 18, 2026

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Patrick Marschner, Kai Ringwald, Marc Thill

|Mar 06, 2026

Real-world progression-free survival and overall survival in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.

Peter A Fasching, Cosima Brucker, Thomas Decker

|Dec 21, 2024

Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Marc Thill, Mark-Oliver Zahn, Anja Welt

|Feb 22, 2023

Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.

M Thill, M-O Zahn, A Welt

|May 18, 2022

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.

Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen

|May 23, 2019

VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.

Thomas Decker, Norbert Marschner, Axel Muendlein

Pageof 1

Frequent Collaborators

2 joint publications

Anja Welt

1 joint publications

Geoffrey J Lindeman

1 joint publications

Tharu M Fernando

1 joint publications

Steve McCune

1 joint publications

Anne Armstrong

1 joint publications

Catherine Shannon

1 joint publications

Ching-Wei Chang

1 joint publications

Patrick Marschner

1 joint publications

Kai Ringwald

1 joint publications

Nina Haug

Frequent Collaborators

2 joint publications

Anja Welt

1 joint publications

Geoffrey J Lindeman

1 joint publications

Tharu M Fernando

1 joint publications

Steve McCune

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on : Mar 14, 2019

See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on : Mar 14, 2019

See more related videos